Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-Current Assets (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Non-Current Assets for 4 consecutive years, with $102.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 35.33% to $102.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $480.4 million through Dec 2025, down 31.7% year-over-year, with the annual reading at $102.9 million for FY2025, 35.33% down from the prior year.
  • Non-Current Assets for Q4 2025 was $102.9 million at Century Therapeutics, down from $107.0 million in the prior quarter.
  • The five-year high for Non-Current Assets was $255.9 million in Q2 2023, with the low at $102.9 million in Q4 2025.
  • Average Non-Current Assets over 4 years is $168.6 million, with a median of $163.0 million recorded in 2022.
  • The sharpest move saw Non-Current Assets surged 71.97% in 2023, then tumbled 41.53% in 2025.
  • Over 4 years, Non-Current Assets stood at $166.8 million in 2022, then grew by 10.11% to $183.7 million in 2023, then decreased by 13.35% to $159.2 million in 2024, then crashed by 35.33% to $102.9 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $102.9 million, $107.0 million, and $124.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.